https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2023#:~:text=Epidiolex%2FEpidyolex%20net%20product%20sales,through%20the%20end%20of%202024.
Anxiety and Insomnia has potentially a far greater market application / reach then Epidiolex...do the numbers yourself
they stack up
Ann: March 2024 Quarterly Activities Report & Appendix 4C, page-21
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $540 | 270K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 13918600 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 41116983 | 27 |
View Market Depth
| Last trade - 10.35am 05/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |